Biom Therapeutics

Bio-pharmaceutical company developing therapeutics for rare neurological childhood diseases

Learn More

A B O U T   U S

Biom Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for brain disorders.

Our mission is to improve human health and quality of life by developing innovative drugs for treating and possibly reversing the effects of hard-to-treat diseases such as rare epilepsies, Alzheimer’s disease and Autism. Biom’s initial focus is on rare pediatric epilepsy such as developmental and epileptic encephalopathies and Angelman syndrome.

PRODUCT PIPELINE

We have a product pipeline of clinical stage drug candidates targeting rare diseases including developmental and epileptic encephalopathies. Our lead product candidate Bio017 has proven to be generally safe and well tolerated in both acute and long-term use with preliminary evidence showing its effectiveness.

PRODUCT PIPELINE

We have a product pipeline of clinical stage drug candidates targeting rare diseases including developmental and epileptic encephalopathies. Our lead product candidate Bio017 has proven to be generally safe and well tolerated in both acute and long-term use with preliminary evidence showing its effectiveness.

VISION

Leader in effective and affordable therapeutics for neurological disorders.

MISSION

To improve human health and quality of life by developing innovative drugs for managing and treating diseases ranging from rare epilepsies to Alzheimer’s disease.

2020: A TRANSFORMATIVE YEAR FOR BIOM THERAPEUTICS

2020: Critical Commercialization milestone completed

Preclinical study published in Journal of Clinical Investigation
Shows safety and efficacy data BIO017 in Angel Syndrome mouse model
Clinical open label study show drug substance safety and preliminary efficacy profile
Filed for Orphan Disease Designation for BIO017
Securing patent rights for novel cannabinoid drug delivery
Partnered with Canopy Growth and Alchem

2021: A Transformative Year for Biom Therapeutics

IND-filing in Q1 2021
Randomized Controlled Pivotal study of BIO017 in Angelman Syndrome
Patients

2020: A TRANSFORMATIVE YEAR FOR BIOM THERAPEUTICS

Lead Drug Candidate: BIO017

Developmental & epileptic encephalopathy syndromes – Phase 2 trial positive top-line data
Angelman syndrome – preclinical safety and efficacy data
4Q 2021 DEE – Pivotal Phase 3 SATURN trial topline data

BIO018

Alzheimer initial preclinical data
HIV initial preclinical data
Autism spectrum disorders preclinical data

Overview of

BIOM THERAPEUTICS

  • Leading regional Company headquartered in Sarasota
  • Experienced, professional senior management team
  • Partnerships with Top Pharmaceutical Companies, Federal and State Agencies, and major Epilepsy Academic Centers

Overview of

BIOM THERAPEUTICS

  • Leading regional Company headquartered in Sarasota
  • Experienced, professional senior management team
  • Partnerships with Top Pharmaceutical Companies, Federal and State Agencies, and major Epilepsy Academic Centers

PARTNERSHIP WITH US

Top Pharmaceutical Companies, Federal and State Agencies, and major Epilepsy Academic Centers

RESEARCH & CLINICAL PROGRAMS

Biom’s R & D capabilities includes state-of-the-art biomedical research facility and a team of biomedical researchers. We have a dosage formulation lab to develop various forms of the pharmaceutical-grade formulation.

Read More